Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Benlysta IV Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Benlysta IV (belimumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Advantage Part B coverage and prior authorization criteria for intravenous Benlysta in patients aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis receiving standard therapy.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyBenlysta IV (belimumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting the covered indication, prior therapies and responses, and all applicable disease-specific criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Age 5+Minimum age for covered use
    ≥6Initial SLE score
    >30 IU/mL or >1:80Serologic threshold
    Class 3, 4, or 5Lupus nephritis biopsy
    1 yr / 2 yr

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage duration
    10 mgBilling unit

    Covered Uses and Clinical Requirements

    Covered uses

    Covered for patients aged 5 years and older receiving standard therapy when either covered indication is met.

    Covered indications

    • Active systemic lupus erythematosus: Patient is at least 5 years old, has active systemic lupus erythematosus, and is receiving standard therapy.≥5 years
    • Active lupus nephritis: Patient is at least 5 years old, has active lupus nephritis, and is receiving standard therapy.≥5 years

    Initial systemic lupus erythematosus therapy

    Initial SLE coverage requires all of the following.

    Initial SLE coverage

    • Age: Patient is 5 years of age or older.≥5 years
    • Disease activity: SELENA-SLEDAI score before starting Benlysta is 6 or more.≥6
    • Serologic criterion

      • Anti-dsDNA antibody is greater than 30 IU/mL.>30 IU/mL
      • ANA is greater than 1:80.>1:80

    Initial lupus nephritis therapy

    Initial lupus nephritis coverage requires all of the following.

    Initial lupus nephritis coverage

    • Age: Patient is 5 years of age or older.≥5 years
    • Confirmed SLE: Diagnosis of systemic lupus erythematosus is confirmed.
    • Kidney biopsy confirms class 3, 4, and/or 5 disease.Class 3, 4, and/or 5

    Prescriber requirements

    Prescriber qualification is required.

    Prescriber restriction: Prescriber must be a specialist in treating the condition or must have consulted with a specialist.

    Benlysta must not be used concurrently with another biologic drug or Lupkynis. Requests involving either excluded concomitant therapy do not meet the coverage criteria.

    Billing and Clinical Reference Values

    Covered HCPCS CodesHCPCSCovered
    J0490Benlysta IV (belimumab) vial; billing unit: 10 mg
    Patient age
    Minimum age5 years and older
    Covered SLE useActive systemic lupus erythematosus while receiving standard therapy
    Covered LN useActive lupus nephritis while receiving standard therapy
    SELENA-SLEDAI score
    Required scoreSELENA-SLEDAI score of 6 or more
    Applies toInitial systemic lupus erythematosus coverage
    TimingScore must be documented before starting Benlysta

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Documentation Required

    Prior authorization requires medical records supporting the requested medically accepted indication, including the patient’s prior therapies and responses to treatment.

    Documentation Required

    Required Medical Records

    For any medically accepted indication, submit records that establish the diagnosis and clinical rationale for Benlysta IV, including documentation of prior therapies and the patient’s response to those treatments.

    Documentation Required

    SLE Clinical Documentation

    For initial coverage of active systemic lupus erythematosus (SLE), document the pretreatment disease activity and serologic findings.

    Policy and Drug Background

    Benlysta (belimumab) is a B-lymphocyte stimulator (BLyS)-specific inhibitor. This policy covers intravenous Benlysta for patients 5 years of age and older who are receiving standard therapy for active systemic lupus erythematosus (SLE) or active lupus nephritis (LN). Disease-specific evidence is required for initial coverage.

    Key Terms

    Benlysta (belimumab)
    MedicationBenlysta (belimumab)
    Drug classB-lymphocyte stimulator (BLyS)-specific inhibitor
    Covered usesActive systemic lupus erythematosus and active lupus nephritis
    SLE
    AbbreviationSLE
    Full nameSystemic lupus erythematosus
    Policy contextAn active covered indication for Benlysta in patients receiving standard therapy

    Indication-Specific Initial Coverage

    Initial SLE therapy

    Initial SLE coverage requires the following criteria.

    SLE initial therapy: Active systemic lupus erythematosus with standard therapy; SELENA-SLEDAI score is 6 or more before starting Benlysta; and either anti-dsDNA antibody is greater than 30 IU/mL or ANA is greater than 1:80.SELENA-SLEDAI ≥6; anti-dsDNA >30 IU/mL or ANA >1:80

    Patient must be at least 5 years old.

    Initial lupus nephritis therapy

    Initial lupus nephritis coverage requires the following criteria.

    Lupus nephritis initial therapy: Active lupus nephritis with standard therapy, confirmed systemic lupus erythematosus, and a kidney biopsy confirming class 3, 4, and/or 5 disease.Kidney biopsy class 3, 4, and/or 5
    Policy Summary
    PayerGold Coast Health Plan
    PolicyBenlysta IV (belimumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting the covered indication, prior therapies and responses, and all applicable disease-specific criteria.
    SourceLink
    On This Page
    Covered Uses and Clinical RequirementsBilling and Clinical Reference ValuesAuthorization and Documentation RequirementsPolicy and Drug BackgroundKey TermsIndication-Specific Initial Coverage
    Anti-dsDNA antibody
    Required levelGreater than 30 IU/mL
    Applies toInitial systemic lupus erythematosus coverage
    Serologic requirementMeets the serologic requirement when present with a SELENA-SLEDAI score of 6 or more
    ANA
    Required levelGreater than 1:80
    Applies toInitial systemic lupus erythematosus coverage
    Serologic requirementMeets the serologic requirement when present with a SELENA-SLEDAI score of 6 or more
    Kidney biopsy
    Qualifying classesClass 3, 4, and/or 5 disease
    Applies toInitial lupus nephritis coverage
    Required documentationKidney biopsy confirming the qualifying disease class, together with a confirmed diagnosis of SLE
    • SELENA-SLEDAI score of 6 or more before starting Benlysta.
    • Either an anti-dsDNA antibody level greater than 30 IU/mL or an ANA titer greater than 1:80.
    Documentation Required

    Lupus Nephritis Documentation

    For initial coverage of active lupus nephritis, document both the underlying SLE diagnosis and qualifying kidney biopsy findings.

    • Confirmed diagnosis of systemic lupus erythematosus (SLE).
    • Kidney biopsy confirming class 3, 4, and/or 5 lupus nephritis.
    Denial Risk

    Excluded Concomitant Therapy

    Benlysta must not be used concurrently with another biologic drug or Lupkynis. Requests involving either excluded concomitant therapy may be denied.

    • Do not use with another biologic drug.
    • Do not use with Lupkynis.
    Denial Risk

    SLE Initial-Therapy Criteria

    Initial SLE coverage may be denied when the required disease activity and serologic thresholds are not documented or are not met.

    • SELENA-SLEDAI score must be 6 or more before treatment.
    • The request must document either anti-dsDNA greater than 30 IU/mL or ANA greater than 1:80.
    Denial Risk

    Lupus Nephritis Diagnostic Criteria

    Initial lupus nephritis coverage may be denied when SLE is not confirmed or the kidney biopsy does not demonstrate qualifying disease.

    • Confirmed SLE diagnosis is required.
    • Biopsy must confirm class 3, 4, and/or 5 lupus nephritis.
    Prior Authorization

    Specialist Involvement

    The prescriber must specialize in treating the patient’s condition or have consulted with a specialist. Document the applicable specialist involvement in the request.

    • Prescriber is a specialist in treating the condition; or
    • Prescriber has consulted with a specialist.
    LN
    AbbreviationLN
    Full nameLupus nephritis
    Policy contextAn active covered indication for Benlysta in patients receiving standard therapy

    Patient must be at least 5 years old.